{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:23:20Z","timestamp":1793924600239,"version":"4.8.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T00:00:00Z","timestamp":1475452800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Dermatol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12895-016-0051-4","type":"journal-article","created":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T07:50:20Z","timestamp":1475481020000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial"],"prefix":"10.1186","volume":"16","author":[{"given":"Kim A.","family":"Papp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Soung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Draelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Mamolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Purohit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Ports","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,3]]},"reference":[{"key":"51_CR1","unstructured":"World Health Assembly 67. Psoriasis 2014. http:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA67\/A67_R9-en.pdf . Accessed 27 Jan 2016."},{"key":"51_CR2","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1046\/j.1087-0024.2003.09102.x","volume":"9","author":"RS Stern","year":"2004","unstructured":"Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136\u20139.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"51_CR3","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","volume":"149","author":"H Yeung","year":"2013","unstructured":"Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149:1173\u20139.","journal-title":"JAMA Dermatol"},{"key":"51_CR4","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1111\/jdv.13150","volume":"29","author":"PC Kerkhof van de","year":"2015","unstructured":"van de Kerkhof PC, Reich K, Kavanaugh A, Bachelez H, Barker J, Girolomoni G, et al. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J Eur Acad Dermatol Venereol. 2015;29:2002\u201310.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"51_CR5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jaad.2008.12.032","volume":"60","author":"A Menter","year":"2009","unstructured":"Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643\u201359.","journal-title":"J Am Acad Dermatol"},{"key":"51_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2310\/7750.2011.10066","volume":"15","author":"K Papp","year":"2011","unstructured":"Papp K, Gulliver W, Lynde C, Poulin Y, Ashkenas J. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg. 2011;15:210\u20139.","journal-title":"J Cutan Med Surg"},{"key":"51_CR7","unstructured":"National Clinical Guideline Centre (UK). Psoriasis: Assessment and Management of Psoriasis. London: Royal College of Physicians (UK); 2012 Oct. National Institute for Health and Clinical Excellence: Guidance. 2012. https:\/\/www.nice.org.uk\/guidance\/cg153 . Accessed 27 Jan 2016."},{"key":"51_CR8","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1111\/j.1468-3083.2011.04113.x","volume":"25","author":"PC Kerkhof van de","year":"2011","unstructured":"van de Kerkhof PC, Kragballe K, Segaert S, Lebwohl M. Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the international psoriasis council. J Eur Acad Dermatol Venereol. 2011;25:1130\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"51_CR9","first-page":"158","volume":"10","author":"RT Brodell","year":"2011","unstructured":"Brodell RT, Bruce S, Hudson CP, Weiss JS, Colon LE, Johnson LA, et al. A multi-center, open-label study to evaluate the safety and efficacy of a sequential treatment regimen of clobetasol propionate 0.05% spray followed by Calcitriol 3 mg\/g ointment in the management of plaque psoriasis. J Drugs Dermatol. 2011;10:158\u201364.","journal-title":"J Drugs Dermatol"},{"key":"51_CR10","first-page":"199","volume":"10","author":"L Barnes","year":"2000","unstructured":"Barnes L, Altmeyer P, Forstrom L, Stenstrom MH. Long-term treatment of psoriasis with calcipotriol scalp solution and cream. Eur J Dermatol. 2000;10:199\u2013204.","journal-title":"Eur J Dermatol"},{"key":"51_CR11","doi-asserted-by":"crossref","unstructured":"Mason AR, Mason J, Cork M, Dooley G, Edwards G. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2009:CD005028.","DOI":"10.1002\/14651858.CD005028.pub2"},{"key":"51_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","volume":"65","author":"A Menter","year":"2011","unstructured":"Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137\u201374.","journal-title":"J Am Acad Dermatol"},{"key":"51_CR13","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","volume":"149","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the national psoriasis foundation surveys, 2003\u20132011. JAMA Dermatol. 2013;149:1180\u20135.","journal-title":"JAMA Dermatol"},{"key":"51_CR14","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/bjd.14018","volume":"173","author":"KA Papp","year":"2015","unstructured":"Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two, randomised, placebo-controlled, Phase 3 trials. Br J Dermatol. 2015;173:949\u201361.","journal-title":"Br J Dermatol"},{"key":"51_CR15","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/bjd.13551","volume":"172","author":"R Bissonnette","year":"2015","unstructured":"Bissonnette R, Iversen L, Sofen H, Griffiths CEM, Foley P, Romiti R, et al. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol. 2015;172:1395\u2013406.","journal-title":"Br J Dermatol"},{"key":"51_CR16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","volume":"386","author":"H Bachelez","year":"2015","unstructured":"Bachelez H, van de Kerkhof PCM, Strohal R, Kubanov A, Valenzuela F, Lee JH, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386:552\u201361.","journal-title":"Lancet"},{"key":"51_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/bjd.12266","volume":"169","author":"WC Ports","year":"2013","unstructured":"Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013;169:137\u201345.","journal-title":"Br J Dermatol"},{"key":"51_CR18","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1007\/s11136-013-0384-y","volume":"22","author":"JC Cappelleri","year":"2013","unstructured":"Cappelleri JC, Bushmakin AG, Harness J, Mamolo C. Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity. Qual Life Res. 2013;22:2489\u201399.","journal-title":"Qual Life Res"},{"key":"51_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/09546634.2014.906033","volume":"26","author":"CM Mamolo","year":"2015","unstructured":"Mamolo CM, Bushmakin AG, Capelleri JC. Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: clinically important difference and responder analyses. J Dermatolog Treat. 2015;26:121\u20133.","journal-title":"J Dermatolog Treat"},{"key":"51_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2307\/3001616","volume":"10","author":"WG Cochran","year":"1954","unstructured":"Cochran WG. Some methods of strengthening the common X2 tests. Biometrics. 1954;10:417\u201351.","journal-title":"Biometrics"},{"key":"51_CR21","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719\u201348.","journal-title":"J Natl Cancer Inst"},{"key":"51_CR22","volume-title":"SAS\/STAT\u00ae 9.3 User\u2019s Guide","author":"SAS Institute Inc","year":"2011","unstructured":"SAS Institute Inc. SAS\/STAT\u00ae 9.3 User\u2019s Guide. Cary, North Carolina: SAS Institute Inc; 2011."},{"key":"51_CR23","doi-asserted-by":"crossref","unstructured":"Krueger J, Clark JD, Su\u00e1rez-Fari\u00f1as M, Fuentes-Duculan J, Cueto I, Wang CQ, Tan H, Wolk R, Rottinghaus ST, Whitley MZ, Valdez H, von Schack D, O\u2019Neil SP, Reddy PS, Tatulych S, for the A3921147 Study Investigators. Tofacitinib attenuates pathologic immune pathways in psoriasis: a randomized Phase 2 study. J Allergy Clin Immunol. 2016;137:1079-90.","DOI":"10.1016\/j.jaci.2015.12.1318"},{"key":"51_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3109\/09546634.2013.861891","volume":"26","author":"AG Bushmakin","year":"2015","unstructured":"Bushmakin AG, Mamolo C, Cappelleri JC, Stewart M. The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib. J Dermatolog Treat. 2015;26:19\u201322.","journal-title":"J Dermatolog Treat"},{"key":"51_CR25","volume-title":"The 23rd World Congress of Dermatology Abstracts and Proceedings Vancouver","author":"T Luger","year":"2015","unstructured":"Luger T, Cappelleri J, Bushmakin A, Mallbris L, Mamolo C. Clinically meaningful improvement in pruritus with tofacitinib: results from a phase 3 program [abstract]. In: The 23rd World Congress of Dermatology Abstracts and Proceedings Vancouver. 2015. http:\/\/derm2015.org\/program\/abstract-volume\/ . Accessed 27 Jan 2016."},{"key":"51_CR26","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/jdv.12081","volume":"28","author":"C Mamolo","year":"2014","unstructured":"Mamolo C, Harness J, Tan H, Menter A. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2014;28:192\u2013203.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"51_CR27","doi-asserted-by":"crossref","unstructured":"Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L, Wang C, Purohit Y, Mamolo C, Papacharalambous J, Ports WC. Topical tofacitinib for atopic dermatitis: A Phase 2a randomised trial. Br J Dermatol. 2016. Epub ahead of print.","DOI":"10.1111\/bjd.14871"},{"key":"51_CR28","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1111\/j.1365-2133.2007.07935.x","volume":"156","author":"SE Chang","year":"2007","unstructured":"Chang SE, Han SS, Jung HJ, Choi JH. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol. 2007;156:1272\u20137.","journal-title":"Br J Dermatol"},{"key":"51_CR29","doi-asserted-by":"publisher","first-page":"64727","DOI":"10.1155\/2007\/64727","volume":"2007","author":"A Reich","year":"2007","unstructured":"Reich A, Szepietowski JC. Mediators of pruritus in psoriasis. Mediators Inflamm. 2007;2007:64727.","journal-title":"Mediators Inflamm"},{"key":"51_CR30","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.ejcb.2011.07.006","volume":"91","author":"C Cornelissen","year":"2012","unstructured":"Cornelissen C, Luscher-Firzlaff J, Baron JM, Luscher B. Signaling by IL-31 and functional consequences. Eur J Cell Biol. 2012;91:552\u201366.","journal-title":"Eur J Cell Biol"},{"key":"51_CR31","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","volume":"117","author":"E Sonkoly","year":"2006","unstructured":"Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117:411\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"51_CR32","doi-asserted-by":"publisher","first-page":"8468","DOI":"10.1021\/jm1004286","volume":"53","author":"ME Flanagan","year":"2010","unstructured":"Flanagan ME, Blumenkopf TA, Brissette WH, Brown MF, Casavant JM, Shang-Poa S, et al. Discovery of CP-690,550: a potent and selective Janus Kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem. 2010;53:8468\u201384.","journal-title":"J Med Chem"}],"container-title":["BMC Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12895-016-0051-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12895-016-0051-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12895-016-0051-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T20:14:12Z","timestamp":1498335252000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcdermatol.biomedcentral.com\/articles\/10.1186\/s12895-016-0051-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,3]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["51"],"URL":"https:\/\/doi.org\/10.1186\/s12895-016-0051-4","relation":{"has-review":[{"id-type":"doi","id":"10.35947\/test\/test0001.3","asserted-by":"object"},{"id-type":"doi","id":"10.5555\/abc12345","asserted-by":"object"}]},"ISSN":["1471-5945"],"issn-type":[{"value":"1471-5945","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,3]]},"article-number":"15"}}